Jounce’s drug, called JTX-2011, helps stimulate the immune system to fight off cancer. The company is targeting biological markers on tumors, hoping to provide more specific, individualized therapy matches for patients.
The Cambridge, Mass.-based company will receive $225 million upfront from Celgene for an option to jointly develop JTX-2011, among other new treatments. Additionally, Celgene will invest $36 million in Jounce for a minority stake.
Jounce, which was founded three years ago and only has 60 employees, could earn up to $2.3 billion in further milestone payments.
The company expects to start clinical trials for JTX-2011 later this year.
More articles on the drug market:
FDA approves Aurobindo’s new pain med
Roche’s blood cancer drug disappoints in clinical trial
PhRMA adds 5 new companies to its ranks, including generic rival Teva
